Xeris Pharmaceuticals Inc. (XERS) Misses Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts XERS Hot Sheet
Join SI Premium – FREE
Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q3 EPS of ($0.39), $0.02 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $11 million versus the consensus estimate of $11.03 million.
For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
- Stardust Power (SDST) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
